Currently out of the existing stock ratings of Kevin Fischbeck, 25 are a SELL (17.24%), 86 are a BUY (59.31%), 34 are a HOLD (23.45%).

Kevin Fischbeck

Work Performance Price Targets & Ratings Chart

Analyst Kevin Fischbeck, currently employed at BAML, carries an average stock price target met ratio of 70.53% that have a potential upside of 21.23% achieved within 229 days.

Kevin Fischbeck’s has documented 303 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SGRY, Surgery Partners at 16-Dec-2024.

Wall Street Analyst Kevin Fischbeck

Analyst best performing recommendations are on CLOV (CLOVER HEALTH INVESTMENTS CORP).
The best stock recommendation documented was for UHS (UNIVERSAL HEALTH SERVICES) at 3/23/2020. The price target of $104 was fulfilled within 16 days with a profit of $33.53 (47.58%) receiving and performance score of 29.74.

Average potential price target upside

of $87.07 (24.25%) on UNH (UNITEDHEALTH GROUP ORPORATED).
of $76.85 (23.4%) on HUM (HUMANA).
of $43.62 (19.23%) on CI (CIGNA CORP).

AGL agilon health AMN AMN Healthcare Services APR Apria CCRN Cross Country Healthcare CI Cigna Corp CLOV Clover Health Investments Corp CNC Centene Corp CYH Community Health Systems DVA DaVita HealthCare Partners HCA HCA Holdings SEM Select Medical Holdings SGRY Surgery Partners THC Tenet Healthcare UHS Universal Health Services UNH UnitedHealth Group orporated ALHC Alignment Healthcare LLC HUM Humana OSCR Oscar Health OSH Oak Street Health OPCH Option Care Health ELV Elevance Health MOH Molina Healthcare CSWC Capital Southwest EHC Encompass Health Corp MD Mednax AGTI Agiliti AHCO Adapthealth Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sean Dodge (RBC)